Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06314958
Recruiting Observational

Stage II/III Colorectal Cancer Recurrence

NCT06314958 · tracked via the Priya Life Science China tracker
Sponsor
City of Hope Medical Center
Phase
Observational
Started
2023-03-15
Last updated
2026-07-07

Condition(s) studied

Colorectal CancerColorectal AdenocarcinomaColorectal Cancer Stage IIColorectal Cancer Stage IIIColorectal Cancer Recurrent

Investigational drug(s) / intervention(s)

CENSURE

CENSURE: A panel of CpG sites, whose methylation level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.

Study summary

This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Stage II (high-risk) or III colorectal cancer (TNM classification, 8th edition). * Received standard diagnostic, staging, and therapeutic procedures as per local guidelines * Received stage-specific curative-intent resection followed by adjuvant chemotherapy. * Confirmed cancer-free survivorship confirmed at the time of study inclusion. Exclusion Criteria: * Lack of written informed consent. * Development of recurrence in the first 6 months following adjuvant chemotherapy completion. * Hereditary colorectal cancer syndromes (identified through genetic testing) * Inflammatory bowel diseases

Primary outcome measure(s)

  • Recurrence-Free Survival — Up to 120 months
    Time from treatment completion to development of recurrence (or death)

Trial sites (4)

FacilityCityRegionStatus
City of Hope Medical Center Monrovia California Recruiting
Second Affiliated Hospital of Dalian Medical University Dalian China Recruiting
Barcelona University Barcelona Spain Recruiting
La Paz University Hospital Madrid Spain Recruiting

More City of Hope Medical Center trials in China

Early Detection of Advanced Adenomas and Colorectal Cancer Recruiting

Other trials for the same condition

The Application Value of Spectral CT in the Accurate Staging of Colorectal Cancer Starting soon
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer Recruiting
To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors Starting soon
A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer Recruiting
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06314958 on ClinicalTrials.gov ↗ ← All trials in China